AP-238
AP-238 is an opioid designer drug related to drugs such as azaprocin and bucinnazine, with around the same potency as morphine.[2] It was first discovered in Italy in the 1960s but was never marketed,[3] subsequently appearing on the illicit market around 2020 and being detected in both Slovenia and the USA.[4][5] See also
References
|